Table 1.
Cross reactivity profiles of mAbs.
| mAb (group) | Isotype | EBOVa | SUDV | TAFV | BDBV | RESTV | MARV |
|---|---|---|---|---|---|---|---|
| ZNP31-1-8 (I) | IgG1 | ++b | ++ | ++ | ++ | ++ | − |
| ZNP41-2-4 (I) | IgG1 | ++ | ++ | ++ | ++ | ++ | − |
| ZNP74-7 (I) | IgG1 | ++ | ++ | ++ | ++ | ++ | − |
| ZNP24-4-2 (II) | IgG1 | ++ | + | ++ | ++ | ++ | − |
| ZNP106-9 (III) | IgG1 | ++ | + | ++ | ++ | − | − |
| ZNP108-2-5 (IV) | IgG1 | ++ | − | ++ | ++ | − | − |
| ZNP105-7 (V) | IgG1 | ++ | − | − | ++ | ++ | − |
| ZNP98-7 (VI) | IgG2a | ++ | − | − | ++ | − | − |
| ZNP35-16-3-5 (VII) | IgG1 | ++ | − | − | − | − | − |
| ZNP62-7 (VII) | IgG2b | ++ | − | − | − | − | − |
a
VLPs of each virus species were used as antigens.
b
Antibody reactivity was evaluated based on ELISAOD450 values at a mAb concentration of 2.5 μg/ml. ++, OD≥ 1.0, +, 0.5<OD<1; −, OD≤0.5.